Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome | Zendy

Rachel Aufforth | Zendy; Pooja Ramakant | Zendy; Samira M. Sadowski | Zendy; Amit Mehta | Zendy; Katarzyna Trebska-McGowan | Zendy; Naris Nilubol | Zendy; Karel Pacák | Zendy; Electron Kebebew | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Pheochromocytoma Screening Initiation and Frequency in von Hippel-Lindau Syndrome

Author(s) -

Rachel Aufforth,

Pooja Ramakant,

Samira M. Sadowski,

Amit Mehta,

Katarzyna Trebska-McGowan,

Naris Nilubol,

Karel Pacák,

Electron Kebebew

Publication year - 2015

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - Uncategorized

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2015-3045

Subject(s) - medicine , pheochromocytoma , natural history , metanephrines , retrospective cohort study , cohort , von hippel–lindau disease , prospective cohort study , pediatrics , surgery , disease

Patients with von Hippel-Lindau (VHL) syndrome have a 25-30% chance of developing pheochromocytoma. Although practice guidelines recommend biochemical and radiological screening every 1-2 years for pheochromocytoma in patients with VHL, there are limited data on the optimal age and frequency for screening.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research